Cara Therapeutics board approves 1-for-3 reverse stock split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2025
0mins
Should l Buy ?
Reverse Stock Split Announcement: Cara Therapeutics has approved a 1-for-3 reverse stock split of its common shares, which will take effect on April 16.
Merger and Name Change: Following the merger with Tvard Therapeutics, Cara's stock will trade under the new name Tvardi Therapeutics and the symbol "TVRD".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
